Global Hereditary Angioedema Therapeutics Market 2023-2027
The hereditary angioedema therapeutics market is forecasted to grow by USD 1647.38 mn during 2022-2027, accelerating at a CAGR of 8.95% during the forecast period. The report on the hereditary angioedema therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of hereditary angioedema, advancements in diagnostic techniques, and growing healthcare infrastructure.
Technavio's hereditary angioedema therapeutics market is segmented as below:
By End-user
- Hospital pharmacies
- Retail pharmacies
- E-commerce
By Product
- C1-esterase inhibitor
- Bradykinin B2 receptor antagonist
- Kallikrein inhibitor
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the growing demand for personalized medicine as one of the prime reasons driving the hereditary angioedema therapeutics market growth during the next few years. Also, development of innovative and effective therapeutics, such as monoclonal antibodies and gene therapy and increasing R and D and funding for orphan drug development will lead to sizable demand in the market.
The report on the hereditary angioedema therapeutics market covers the following areas:
- Hereditary angioedema therapeutics market sizing
- Hereditary angioedema therapeutics market forecast
- Hereditary angioedema therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading hereditary angioedema therapeutics market vendors that include Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Attune Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., CENTOGENE NV, Cipla Ltd., CSL Ltd., Diapharma Group Inc., Intellia Therapeutics Inc., Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Pharming Group NV, Pharvaris NV, Sanofi, and Takeda Pharmaceutical Co. Ltd.. Also, the hereditary angioedema therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.